Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Flexibility: Aranesp Dosing Schedules in Chemotherapy-Induced Anemia
NCT00144131Phase 2Completed
- Sponsor
- Amgen
- Start
- Aug 2005
- Modality
- Erythropoietins, Colony Stimulating Factors
01
Overview
A Phase 2 trial of darbepoetin alfa in anemia, sponsored by Amgen. Started Aug 2005; status: completed.
02
Drugs
darbepoetin alfa
03
Conditions
anemia
Beyond the preview
Go deeper on NCT00144131.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00144131.